FRANCHISE TRADE NOW OPEN AN ACCOUNT
IPO News
Prev Next
As on Jun 25, 2019 12:00 AM Your results on : IPO News    
IndiaMart InterMesh IPO fully bid
25-Jun-2019 (17:11)
IndiaMart InterMesh IPO subscribed 50%
24-Jun-2019 (17:47)
Neogen Chemicals ends with 22.58% premium
08-May-2019 (17:05)
Neogen Chemicals IPO gets strong demand
30-Apr-2019 (15:40)
Neogen Chemicals IPO sees strong demand
26-Apr-2019 (17:54)
Neogen Chemicals IPO subscribed 2.09 times
25-Apr-2019 (17:21)
Neogen Chemicals IPO subscribed 27%
24-Apr-2019 (17:25)
Polycab India spurts on debut
16-Apr-2019 (16:52)
Metropolis Healthcare attracts modest premium on debut
15-Apr-2019 (16:00)

Meanwhile, the S&P BSE Sensex was up 138.73 points, or 0.36% to 38,905.84

Shares of Metropolis Healthcare settled at Rs 959.55 on BSE, a premium of 9.04% over the initial public offer price of Rs 880. The stock debuted at Rs 960 on BSE, a premium of 9.09% to the initial public offer (IPO) price of Rs 880. It hit a high of Rs 981.30 and low of Rs 934.80. On BSE, 6.13 lakh shares were traded on the counter.

The initial public offer (IPO) of Metropolis Healthcare received bids for 4.47 crore shares, as per the National Stock Exchange of India (NSE) data. The issue was subscribed 5.84 times. The issue opened for subscription on 3 April 2019 and closed on 5 April 2019. The price band for the issue was fixed at Rs 877 to Rs 880 per share.

The qualified institutional buyers (QIBs) category was subscribed 8.88 times. The non-institutional investors category was subscribed 3.03 times. The retail individual investors (RIIs) category was subscribed 2.21 times.

On a consolidated basis, Metropolis Healthcare reported net profit of Rs 85.66 crore and net sales of Rs 559.31 crore in nine-months ended December 2018.

Incorporated in 1980 by Dr. Sushil Shah, Metropolis Healthcare is one of the leading diagnostics companies in India. The company offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. Metropolis also offers analytical and support services to clinical research organizations for their clinical research projects. The company has presence across 19 states in India, as of 31 December 2018, with leadership position in the West and South India.

Rail Vikas Nigam ends almost flat on debut
11-Apr-2019 (16:27)
Polycab India IPO subscribed 51.96 times
10-Apr-2019 (17:26)
Polycab India IPO sees strong subscription
09-Apr-2019 (17:41)
Polycab India IPO fully subscribed
08-Apr-2019 (17:28)
Metropolis Healthcare IPO subscribed 5.84 times
08-Apr-2019 (17:23)
Connect with us :   
Globe
About us
Our Services
Milestones
Memberships
Core Values
Investor Relations
Product & Services
Broking
Institutional Broking
PMS
Clearing Services
Distribution
Research
Depository
Trade & Products
Globe Connect Pro
Globe Trade Smart
Globe Connect Mobile/Tablet
Globe News Connect
Globe e-KYC Application
NSDL e-KYC Signer Application
Back Office
Back Office
CMS
CMS-TM
KYC/KDC Status
Mutual Fund
CAMS
RMS Policy
Helpdesk
Download Forms
Useful Links
BSE
NSE
SEBI
RBI
MCX
NCDEX
Exchange Holidays
Anti-Money Laundering Policy
Policies, Procedures, Rights, Obligations and RDD

Funds Payout Policy

Shortages Obligation Arising Out Of Internal Netting of Trades

Policies of Globe Commodities Limited
Guidance Note on FATCA and CRS May 2016
Right and Obligation, RDD, Guidance Note in Vernacular Language - Equity | Commodity
Additional Risk Disclosure for Trading into Commodity options
In case of any grievances pleae write to
Investor_trading@globecapital.com /  igr@globecapital.com (For Trading)     globedp@globecapital.com (For DP)    Investor_pms@globecapital.com (For PMS)     
commigr@globecapital.com (For Commodities)
Equity SEBI Registration No INZ000177137. Exchange Registration Nos NSE : TM No. - 06637, Clearing No.- M50302 | BSE : Clearing No.- 3179 | MSEI : TM Code-1004, Clearing Member Code- 4 | SEBI Registration for DP : IN-DP-NSDL-97-99, NSDL- DP ID: IN300966, CDSL DP ID: 12020600 | SEBI Research Analysts Registration No. INH100001187 | SEBI PMS Registration No. INP00000236
* Through subsidiary Globe Commodities Ltd. --> Commodity SEBI Regn. No. - INZ000024939, Exchange Regn. Nos. - MCX CM ID: 8550 TM ID: 10735, NCDEX CM ID: M50011 TM ID: 00012, NMCE ID: CL0111, ICEX ID: 1009, NCDXSPOT-CR-07-10011,
** Through step in subsidiary Globe Comex International DMCC --> DGCX **TM Id.1064, CM Id.3064*
"We also do Pro-Account trading in Commodity Segment.."
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
Attention Investors:
"Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your Stock Brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors"
"Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL/CDSL on the same day......................issued in the interest of investors."
"No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
© 2013 Globe Capital Market Limited. All rights reserved
Designed, Developed and Content powered by CMOTS Infotech (ISO 9001:2015 Certified) Privacy Policy Disclaimer Terms and Conditions